Rituximab for Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Details


( Last Updated : April 29, 2019)
Generic Name:
Rituximab
Project Status:
Cancelled
Manufacturer:
Sandoz Canada
Brand Name:
TBD
Project Line:
Reimbursement Review
Project Number:
PC0180-000

Details


Tumour Type:
Lymphoma & Leukemia
Indications:
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia Biosimilar
Funding Request:
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia
Review Status:
Cancelled
Pre Noc Submission:
Yes
Sponsor:
Sandoz Canada
Clarification:
The submitter notified pCODR that they will not be filing the submission.

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.